Bydgoszcz, Poland

In Vivo

Pneumococcal Infections

Respiratory Syncytial Virus Infections

Merck Sharp & Dohme (MSD)

condition

allSponsorName

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

The purpose of this study is to evaluate the safety, tolerability, and immunogenicity of V116 compared to PPSV23 in children 2 through 17 years of age. Researchers want to learn if V116 is as good as, or is better than the PPSV23 vaccine in terms of the antibody immune response. V116 and PPSV23 will be studied in children and teenagers who have a higher risk of getting invasive pneumococcal disease (IPD).

A Clinical Study of the V116 Vaccine for Children and Teenagers (V116-013)

In Vivo | Bydgoszcz, Poland

Site insights

Work at this site?

Active trials

A Clinical Study of the V116 Vaccine for Children and Teenagers (V116-013) (STRIDE-13)

Trial sponsors